Foghorn Therapeutics Inc. (FHTX) — 10-Q Filings
All 10-Q filings from Foghorn Therapeutics Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
- 10-Q Filing — May 7, 2026
-
Foghorn Narrows Losses, R&D Spend Drops 19% Amid Cash Burn
— Nov 5, 2025 Risk: high
Foghorn Therapeutics Inc. reported a net loss of $15.8 million for the three months ended September 30, 2025, an improvement from the $19.1 million net loss in -
Foghorn Narrows Losses, Boosts Revenue on Collaboration Gains
— Aug 5, 2025 Risk: high
Foghorn Therapeutics Inc. reported collaboration revenue of $16.7 million for the three months ended June 30, 2025, a significant increase from $10.2 million fo -
Foghorn Therapeutics Files Q1 2025 10-Q
— May 14, 2025 Risk: medium
Foghorn Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, headquartered in Cambridge, MA, operates in the pharmaceutical prepa -
Foghorn Therapeutics Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Foghorn Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and first half of 20 -
Foghorn Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024
— May 6, 2024 Risk:
Foghorn Therapeutics Inc. (FHTX) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Foghorn Therapeutics Inc. filed a 10-Q report for the quarterly pe
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX